NF-?B as the mediator of metformin's effect on ageing and ageing-related diseases

Basit Öğe Kaydı
dc.authoridSOYDAS, Tugba/0000-0002-0684-1906|yenmis, guven/0000-0002-6688-9725
dc.authorwosidSOYDAS, Tugba/ACK-6027-2022
dc.contributor.authorSultuybek, Gonul Kanigur
dc.contributor.authorSoydas, Tugba
dc.contributor.authorYenmis, Guven
dc.date.accessioned2024-07-18T20:47:28Z
dc.date.available2024-07-18T20:47:28Z
dc.date.issued2019
dc.departmentİstanbul Bilgi Üniversitesien_US
dc.description.abstractAgeing can be defined as the progressive failure of repair and maintenance systems with a consequent accumulation of cellular damage in nucleic acids, proteins, and lipids. These various types of damage promote ageing by driving cellular senescence and apoptosis. The nuclear factor-kappa B (NF-kB) pathway is one of the key mediators of ageing and this pathway is activated by genotoxic, oxidative and inflammatory stress, and regulates expression of cytokines, growth factors, and genes that regulate apoptosis, cell-cycle progression, and inflammation. Therefore, NF-kB is increased in a variety of tissues with ageing, thus the inhibition of NF-kB leads to delayed onset of ageing-related symptoms and pathologies such as diabetes, atherosclerosis, and cancer. Metformin is often used as an anti-diabetic medication in type 2 diabetes throughout the world and appears to be a potential anti-ageing agent. Owing to its antioxidant, anticancer, cardio-protective and anti-inflammatory properties, metformin has become a potential candidate drug, improving in the context of ageing and ageing-related diseases. An inappropriate NF-kB activation is associated with diseases and pathologic conditions which can impair the activity of genes involved in cell senescence, apoptosis, immunity, and inflammation. Metformin, inhibiting the expression of NF-kB gene, eliminates the susceptibility to common diseases. This review underlines the pleiotropic effects of metformin in ageing and different ageing-related diseases and attributes its effects to the modulation of NF-kB.en_US
dc.identifier.doi10.1111/1440-1681.13073
dc.identifier.endpage422en_US
dc.identifier.issn0305-1870
dc.identifier.issn1440-1681
dc.identifier.issue5en_US
dc.identifier.pmid30754072en_US
dc.identifier.scopus2-s2.0-85062797192en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage413en_US
dc.identifier.urihttps://doi.org/10.1111/1440-1681.13073
dc.identifier.urihttps://hdl.handle.net/11411/7804
dc.identifier.volume46en_US
dc.identifier.wosWOS:000465021700002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofClinical and Experimental Pharmacology and Physiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAgeingen_US
dc.subjectAgeing-Related Diseasesen_US
dc.subjectMetforminen_US
dc.subjectNf-Kben_US
dc.subjectOxidative Stressen_US
dc.subjectFree-Radical Productionen_US
dc.subjectMatrix-Metalloproteinase Expressionen_US
dc.subjectDna-Damageen_US
dc.subjectOxidative Stressen_US
dc.subjectInsulin-Resistanceen_US
dc.subjectBreast-Canceren_US
dc.subjectNondiabetic Subjectsen_US
dc.subjectActivationen_US
dc.subjectSenescenceen_US
dc.subjectCellsen_US
dc.titleNF-?B as the mediator of metformin's effect on ageing and ageing-related diseases
dc.typeReview Article

Dosyalar

Koleksiyon

Web of Science Indexed Publications
PubMed Indexed Publications
Scopus Indexed Publications